This company develops software that connects biosensors and drug infusion pumps to automate insulin delivery. Their system uses adaptive feedback loops to personalize and deliver medication in real-time, improving diabetes management.
Funding
Funding not disclosed
Founders
Product
Problem
Individuals with diabetes often struggle to maintain optimal glycemic control, requiring frequent manual adjustments to insulin delivery based on glucose monitoring and carbohydrate intake. This manual process can be burdensome, prone to errors, and may lead to both hypo- and hyperglycemic events.
Solution
InsuLearn develops Software as a Medical Device (SaMD) that automates insulin delivery by linking continuous glucose monitors (CGMs) with insulin pumps. Their system employs adaptive feedback loops and machine learning algorithms to personalize insulin delivery in real-time, based on an individual's glucose trends and insulin history. By separating the software from the hardware, InsuLearn aims to create a patient-centric, closed-loop system that reduces the burden of diabetes management and improves overall health outcomes. The technology adapts to individual needs, optimizing insulin parameters to maintain stable blood glucose levels.
Target Audience
The primary target audience includes individuals with Type 1 and Type 2 diabetes who require insulin therapy and are looking for automated solutions to improve glycemic control and reduce the burden of diabetes management.
Features
- Adaptive feedback loops that adjust insulin delivery based on real-time glucose readings from CGMs
- Machine learning algorithms that personalize insulin delivery parameters based on individual glucose and insulin history
- Software as a Medical Device (SaMD) approach, allowing for compatibility with various CGM and insulin pump hardware
- Real-time data analysis and automated adjustments to minimize hypo- and hyperglycemic events